Pfizer’s Outlook Improves
Pfizer’s Outlook Improves Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter
Pfizer’s Outlook Improves Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter
Schering’s Dr. Feelbetter? Fred Hassan is out to revive the drugmaker. It’s a big job
Get new actionable insights and updates from BiotechBlog